Nuvectis Pharma Q2 Loss Widens From Higher Costs, Shares Down

(RTTNews) - On Tuesday, Nuvectis Pharma, Inc. (NVCT), a clinical stage biopharma company, reported wider loss in the second quarter of 2026 due to higher costs

On the Nasdaq, the shares were trading 7.06 percent down at $20.08.

Net loss attributable to the common shareholders for the period widened to $7.02 million from $6.33 million in the same quarter last year. On a per share basis, loss was $0.30, in line with the prior year.

Operating loss for the period widened to $7.20 million, from $6.60 million in the previous year.

Research and Development costs rose to $4.68 million from $3.61 million a year ago.

General and Administrative expenses, on the other hand, dropped to $2.51 million from $2.98 million last year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.